CASE HISTORY {#s1}
============

A 4-yr-old boy with a previously unremarkable medical history presented with 6 wk of vomiting and horizontal gaze palsy. His family history was remarkable for the recent death of his mother reportedly from metastatic carcinoma at age 27, and he had a healthy 6-mo-old sister. His father was healthy at age 30, with no personal history of cancer, and his paternal grandfather had died of cancer of unknown type, possibly of renal origin.

Magnetic resonance imaging (MRI) revealed multiple lesions compatible with tumor involving the patient\'s brainstem and left temporal lobe. No resection was attempted, and the patient was treated with a presumptive diagnosis of infiltrative glioma with carboplatin and vincristine. After 1 mo, he reported worsening nausea and dizziness, and MRI showed tumor progression. He underwent biopsy and ventriculoperitoneal shunt placement.

Biopsy of the brainstem lesion showed a highly cellular infiltrative astrocytoma with marked proliferative activity ([Fig. 1](#MCS002576COTF1){ref-type="fig"}A--C) consistent with glioblastoma. The patient received treatment with involved-field radiation therapy and temozolomide. One-month follow-up MRI postcompletion of chemoradiotherapy showed diffuse leptomeningeal enhancement, and cerebrospinal fluid (CSF) cytology confirmed dissemination of tumor. His tumor tissue was sent to the Children\'s Hospital Los Angeles (CHLA) Center for Personalized Medicine for further analysis.

![Histologic features of proband astrocytoma and maternal choriocarcinoma. The proband\'s brainstem astrocytoma showed a diffusely infiltrative pattern of growth (*A*) and a markedly elevated proliferative index (Ki-67) (*B*). Immunoreactivity for p53-D07 was strong and diffuse (*C*). The maternal submucosal gastric mass was hemorrhagic and necrotic with marked pleomorphism (*D*) and a very high proliferative index (Ki-67) (*E*). Immunoreactivity for p53-D07 was strong and diffuse in the choriocarcinoma cells, but absent in the adjacent gastric mucosa (*F*).](MCS002576Cot_F1){#MCS002576COTF1}

Chromosomal microarray testing performed on the astrocytoma tissue showed an extremely complex pattern of chromosomal gains and losses and three regions of chromosomal amplification that included *MYCN* and *KRAS*. Four copies of Chromosome 7, deletion of *CDKN2A*, and loss of heterozygosity (LOH) for the short arm of Chromosome 17 were also noted ([Fig. 2](#MCS002576COTF2){ref-type="fig"}A). The complex nature of the abnormalities was consistent with the histologic diagnosis of glioblastoma. Sanger sequencing of *TP53* demonstrated the presence of a c.844C\>T mutation, predicted to result in a p.Arg282Trp missense mutation at the protein level ([Fig. 2](#MCS002576COTF2){ref-type="fig"}B). The wild-type allele was absent, consistent with the LOH observed by chromosomal microarray analysis of the tumor. Given the pathogenic mutation in the tumor, germline *TP53* mutation testing was recommended.

![Findings from molecular genetic analysis of tumor tissue. Chromosomal microarray performed on the proband\'s astrocytoma tissue. A complex pattern of gains and losses is observed. Key features include deletion of *CDKN2A* and loss of heterozygosity for 17p (*A*). Sanger sequencing. *Top* trace shows wild-type control, *central* trace shows the maternal gastric tumor with heterozygous pattern attributed to mixture of normal and tumor cells. The proband\'s astrocytoma with normal *TP53* allele loss is shown in the *lower* trace, marked by an arrow (*B*). Pedigree from the proband\'s immediate family (*C*). Solid symbols (squares, males; circles, females) indicate clinically affected individuals; slashed symbols indicate deceased individuals. Green, Li--Fraumeni syndrome; red, metastatic choriocarcinoma.](MCS002576Cot_F2){#MCS002576COTF2}

Sanger sequencing demonstrated the presence of the c.844C\>T mutation in the patient\'s blood. A recommendation for *TP53* testing was extended to his immediate family, including his father and younger sister. The patient\'s father was shown to be a carrier of the c.844C\>T mutation ([Fig. 2](#MCS002576COTF2){ref-type="fig"}C), and the child\'s sibling was found to have the same *TP53* mutation. The sibling shows no evidence of disease (including normal serum β-hCG level) and is undergoing continued surveillance. Further testing of the paternal family has been recommended but is not yet complete.

The proband\'s brain tumor continued to progress, leading to his demise 8 months after initial diagnosis. Autopsy revealed extensive leptomeningeal dissemination of glioblastoma, which was strongly and diffusely positive for p53 immunoexpression.

REVIEW OF MATERNAL TUMOR PATHOLOGY {#s2}
==================================

Because the patient\'s mother was originally presumed to be the carrier parent, tissue samples from her tumor were requested from the originating pathology department for further evaluation. Additional clinical history was also received. She initially presented with acute gastrointestinal bleeding 4 months after the birth of her second child and was found to have diffusely metastatic disease involving the stomach, lungs, liver, and brain. Upon pathologic review, the mother\'s tumor was determined to be metastatic choriocarcinoma to the stomach and lung ([Fig. 1](#MCS002576COTF1){ref-type="fig"}D--F). Key histologic features included marked nuclear pleomorphism, degenerative changes, syncytiotrophoblastic giant cells with immunoreactivity for inhibin and β-hCG, and markedly elevated proliferative activity (Ki-67 labeling index \> 70%). Strong and diffuse p53 immunoreactivity was present in the gastric tumor sample but not in the adjacent gastric mucosa.

*TP53* testing was performed on the mother\'s gastric tumor tissue at the CHLA Center for Personalized Medicine. The same c.844C\>T *TP53* mutation was detected in the maternal tumor tissue as was identified in the proband, father, and sibling. Sanger sequencing of a macro-dissected region of the histologically normal gastric mucosa was negative for the *TP53* mutation, confirming that the mutation was not present in the mother\'s germline ([Table 1](#MCS002576COTTB1){ref-type="table"}). Chromosomal microarray analysis of the tumor revealed a complex pattern of copy-number gains and losses that was distinct from the child\'s brain tumor, and a mixed genotype pattern consistent with derivation from two individuals (data not shown).

###### 

Sequence variants identified from tumor samples

  Subject   Tumor                         Gene     Chr   HGVS DNA                 HGVS Protein   Variant type   Predicted effect   dbSNP ID     Genotype                                               Parent of origin
  --------- ----------------------------- -------- ----- ------------------------ -------------- -------------- ------------------ ------------ ------------------------------------------------------ ------------------
  Proband   Astrocytoma                   *TP53*   17    NM_000546.5: c.844C\>T   p.Arg282Trp    SNV            Missense           rs28934574   Tumor homozygous (LOH Chr 17); germline heterozygous   Father
  Mother    Gestational choriocarcinoma   *TP53*   17    NM_000546.5: c.844C\>T   p.Arg282Trp    SNV            Missense           rs28934574   Tumor heterozygous; germline negative                  N/A

HGVS, Human Genome Variation Society; dbSNP, the Single Nucleotide Polymorphism database; SNV, single-nucleotide variant; LOH, loss of heterozygosity; N/A, not applicable.

DISCUSSION {#s3}
==========

Remarkably, the transmission of a paternal *TP53* mutation to a maternal partner has been previously reported: a 37-yr-old French male index case with cholangiocarcinoma had a child diagnosed at 5 mo of age with metastatic choriocarcinoma. Subsequently, choriocarcinoma was diagnosed in the child\'s mother 13 mo after delivery. Genotyping of metastases in both child and mother showed the tumors to be genetically similar and confirmed the paternal origin of the *TP53* mutation. This remains, to our knowledge, the only other genetically confirmed case of transmission of *TP53* mutation resulting in a neoplasm in a female partner. The authors of that report highlight data from the French LFS registry suggesting that this outcome may occur in up to 1% of the deliveries in partners of *TP53* mutation carriers. Two of 213 pregnancies gave rise to gestational choriocarcinoma; however, these cases could not be genetically confirmed to harbor *TP53* mutations. Of the two other presumed (not genetically confirmed) cases described, one was identified retrospectively: a young woman with breast cancer at age 36 was found to have a *TP53* mutation of paternal origin and had a family history of choriocarcinoma in her mother (who died at age 22). Another case of gestational choriocarcinoma was reported in the female partner of a known *TP53* mutation carrier. Tumor DNA was not available for molecular analysis of either of these cases. Overall the incidence of choriocarcinoma in partners of LFS patients could be up to 500-fold that of the general population ([@MCS002576COTC7]). Our review of publicly available data from the National Cancer Institute\'s LFS cohort did not reveal cases of gestational choriocarcinoma among LFS patients, but this registry may not routinely collect or report data from partners of LFS patients. Of note, a recent report described the first known case of choriocarcinoma in a patient who herself harbored a germline *TP53* mutation ([@MCS002576COTC1]). Choriocarcinoma has not previously been considered a common LFS-associated malignancy.

Gestational choriocarcinoma is a subtype of the gestational trophoblastic neoplasms, a set of rare tumors that also includes placental site trophoblastic tumor and epithelioid trophoblastic tumor. These tumors are often associated with an antecedent molar pregnancy but can arise after a spontaneous abortion, ectopic pregnancy, or normal pregnancy, as is suspected in this case. Genotyping of choriocarcinomas from term pregnancies frequently reveals biparental genetic contribution, suggesting these tumors are genetically related to the antecedent pregnancy ([@MCS002576COTC9]). In this case, the complex copy-number profile of the choriocarcinoma tissue precluded our ability to definitively interpret the parental contribution to the tumor. A mixture of wild-type *TP53* with mutant *TP53* could represent either a biparental genotype or, alternatively, a commingling of normal tissue (such as endothelial cells or inflammatory cells) with the tumor.

Length of time to presentation after the index pregnancy can vary significantly, and higher risk profiles are associated with an interval of \>2 mo ([@MCS002576COTC6]). In this case, the patient also presented with disseminated disease including brain metastasis, a feature of the highest risk category (FIGO stage 4).

Here we report the second sequencing-confirmed case of paternal transmission of a germline *TP53* mutation resulting in a choriocarcinoma arising in a female partner. The relationship of the *TP53* mutation to the pathogenesis of choriocarcinoma is not fully understood. In separate studies, *TP53* mutations or elevated levels of wild-type p53 protein have been demonstrated in choriocarcinoma cell lines, ([@MCS002576COTC3]; [@MCS002576COTC13]), but there are conflicting reports regarding the prevalence of *TP53* mutations in human choriocarcinoma tissue samples ([@MCS002576COTC10]; [@MCS002576COTC2]). Alterations in ASPP proteins, which regulate p53, may be a more common tumorigenic pathway in choriocarcinoma, and they may account for the increased levels of p53 protein observed in human tissue samples ([@MCS002576COTC4], [@MCS002576COTC5]).

Based on this case and recent literature, female partners of LFS patients may have an increased risk of choriocarcinoma after parental--fetal transmission of germline *TP53* mutation from male carriers. Although the Toronto protocol has established an effective approach to detect tumors and improve overall survival in children and adults with inherited cancer susceptibility, there is a need to expand the current criteria to include surveillance of female partners of LFS patients for gestational trophoblastic disease, even after normal delivery. Early determination of carrier status of the child after birth should prompt even more thorough investigation of the mother. After molar pregnancy, current guidelines advise weekly serum β-hCG testing to monitor for gestational trophoblastic neoplasia ([@MCS002576COTC6]). In female partners of LFS patients after normal delivery, a similar approach could be used to follow serum β-hCG levels to zero. A plateaued or rising β-hCG should prompt further clinical investigation. The optimal length of time for monitoring is unclear, but given the reported choriocarcinoma in a female partner of an LFS patient at 13 mo after delivery, a year of monitoring may be appropriate ([@MCS002576COTC7]). Furthermore, detailed pathologic examination of the placenta should be performed to evaluate for intraplacental choriocarcinoma. Recognition of this unique mode of transmission of germline *TP53* mutations may also further inform discussions about family planning with female partners of LFS patients; not only to prevent unwanted pregnancy, but also to reduce their own risk of developing cancer.

This case underscores the importance of integrating molecular techniques into tumor diagnostics. Particularly in the pediatric population, germline alterations can be suspected on the basis of tumor sequencing or copy-number-based genetic studies. In this specific case, recognition of this unusual LFS family was facilitated by the genetic analysis of their child\'s brain tumor tissue. The complex pattern of copy-number variation observed in the tumor tissue was considered suspicious for a *TP53*-driven tumor, and subsequent Sanger sequencing was confirmatory. Codon 282 of *TP53* is a known hotspot for single base substitution, and R282W (arginine to tryptophan) mutant is significantly associated with shortened survival time and earlier onset age in LFS ([@MCS002576COTC12]). Identification of this mutation at an early age can allow for close surveillance of this patient\'s sibling for malignancy. Surveillance protocols developed for individuals with LFS have demonstrated improved long-term survival for these patients ([@MCS002576COTC8]; [@MCS002576COTC11]).

Not only has molecular testing in tumor pathology established a key role in the diagnosis, prognostication, and management of individual patients, but it can also reveal information of profound clinical significance to their family members. This case is an excellent example of how the routine performance of molecular testing in neuropathology and other surgical pathology specialties is expanding our understanding of familial tumor syndromes. It also demonstrates the significance of interpreting cancer genetics in the context of constitutional testing.

METHODS {#s4}
=======

Genomic DNA was extracted from frozen tissue from the proband\'s brain tumor using a commercially available kit (QIAGEN QIAamp DNA Mini Tissue Kit). Genomic DNA from the maternal gastric tumor sample was extracted from formalin fixed paraffin embedded (FFPE) tissue, using a commercially available kit (QIAGEN QIAamp DNA FFPE Tissue Kit). Chromosomal microarray analysis of the brain tumor sample was performed according to the manufacturer\'s protocols (OncoScan FFPE Assay Kit, ThermoFisher Scientific).

Exon 8 of the *TP53* gene (NM_000546.5) was amplified using primers developed by CHLA (forward: 5′-GCTCCAGAAAGGACAAGGG-3′; reverse: 5′-GTTATGCCTCAGATTCACTTTT-3′). Sanger sequencing was performed using the Big Dye Terminator v1.1 (Life Technologies, ThermoFisher Scientific) on an automated fluorescent sequencer (ABI 3730 Genetic Analyzer, Applied Biosystems, ThermoFisher Scientific).

Analysis of saliva samples from the father and children was performed at Ambry Genetics. The CHLA Center for Personalized Medicine provides fee-for-service *TP53* sequencing and chromosomal microarray testing.
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